Nike Earnings at Risk as UBS Cuts Price Target to $42 
White House Bars CNN, MS NOW and Politico Reporters 
US-China Talks Target AI, Tariffs Ahead of Trump-Xi Summit 
Wall Street Mixed as Treasury Yields Rise After Fed Hike 
NASA, Boeing Discuss Expanding Starliner Missions 
Asia Stocks Rise on AI Demand as Oil Eases 
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center 
France Debt-to-GDP Ratio Seen Hitting Record 119.3% in 2026 
Supertanker Orders Surge as US-Iran War Reshapes Oil Trade 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Meta Partners With Shopify to Bring Shop Pay Checkout to Muse AI 
Gold Prices Slip as Strong Dollar and Hawkish Fed Pressure Bullion 
Bolivia Approves $1.9 Billion IMF Financing Deal 
Petrobras Joins Brazil Diesel Subsidy Program 
Fed Rate Hike Threatens Housing as U.S. Growth Leans on AI, Citi Says 
Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
Add as a preferred source on Google
Samsung Biologics signed a contract manufacturing organization (CMO) deal with GreenLight Biosciences to produce COVID-19 vaccines for poor nations, particularly in Africa. The South Korean pharma company revealed its new partnership agreement with the Boston-based biotech firm on Thursday, Nov. 25.
Samsung Biologics and GreenLight Biosciences’ goal is to bring vaccines to everyone as they want to have a world that has the ability to produce sufficient messenger RNA vaccine doses for billions of people per year.
As per The Korea Herald, the agreement between the companies stated that the Korean pharma company would produce drug materials for GreenLight’s COVID-19 vaccine candidate. The two firms also agreed to scale up research and manufacturing efforts so they can be able to allocate more coronavirus vaccines for underdeveloped countries.
Samsung’s pharma unit added that it would be expanding its production plant in Songdo, Incheon, by building new facilities on the site. The constructions are expected to be completed by April next year.
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” Samsung Biologics chief executive officer, John Rim, said in a press release. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from Drug Substance (DS) to Aseptic Fill Finish (DP) to commercial release, all from a single site.”
Meanwhile, GreenLight Biosciences is also reported to be in the last stage of finalizing its partnership deal with a local partner in Africa. This is a separate agreement with Samsung Biologics, and after the contracts are sealed, the American biotech company is planning to start the phase 1 clinical trials for its vaccine candidate as early as the first quarter of 2022, as per Korea Joongang Daily.
Samsung Biologics and GreenLight Biosciences are producing COVID-19 vaccines using mRNA or messenger ribonucleic acid. This is the same type applied to Pfizer and Moderna vaccines.
Finally, Andrey Zarur, GreenLight CEO, said they are happy to join forces with Samsung to make messenger RNA for their Covid vaccine trial as there is an urgent need to develop vaccines for the whole world.
